Evidence map›Paper›PMID 41050066›Full record

ArticleOncology research2025

3

Wenjing Liao, Liaodi Wang, Zhen Huang, Ziyu Zou, Yimin Liu, Haoyue Liu, Zhaoning Duan, Liangdan Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjing LiaoDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Liaodi WangDepartment of Radiology, Ping An Healthcare Diagnostics Center, Wuhan, 430014, China.
Zhen HuangDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ziyu ZouDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yimin LiuDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Haoyue LiuDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zhaoning DuanDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Liangdan TangDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Ovarian cancer (OC) is a highly heterogeneous disease characterized by high metastatic potential and frequent recurrence. 3β-hydroxysterol Δ24-reductase (DHCR24) is closely associated with the progression of various malignant tumors, but its role in OC remains unexplored. This study is the first to systematically investigate the function of DHCR24 in OC and elucidate its mechanism in promoting OC progression, providing novel theoretical insights for targeted therapy. Methods: The expression of DHCR24 was evaluated in tissues using bioinformatics and clinical data; the impact of DHCR24 on the malignant behavior of OC was assessed through Results: Database, clinical data, and immunohistochemical (IHC) analyses demonstrated that DHCR24 is upregulated in OC and correlates with poor outcomes. Conclusion: DHCR24 contributes to ovarian cancer progression by upregulating the TGF-β1 pathway, highlighting its potential as a therapeutic target in ovarian cancer.

Indexed as

Nerve Tissue ProteinsOvarian NeoplasmsOxidoreductases Acting on CH-CH Group DonorsSmad2 ProteinSmad3 ProteinTransforming Growth Factor beta1AnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMiceDHCR24 protein, humanNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTGFB1 protein, humanTransforming Growth Factor beta13β-hydroxysterol Δ24-reductase (DHCR24)metastasisovarian cancer (OC)proliferationtransforming growth factor beta (TGF-β1)

Identifiers

PMID41050066
PMCPMC12494117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.